Tufts CSDD Releases Findings from Diabetes Study

September 23, 2016

According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development.

According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.

Read the full release here

Related Content:

News